Molecular characterization and drug resistance patterns of Mycobacterium tuberculosis complex in extrapulmonary tuberculosis patients in Addis Ababa, Ethiopia.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
06
2020
accepted:
20
11
2020
entrez:
7
12
2020
pubmed:
8
12
2020
medline:
28
1
2021
Statut:
epublish
Résumé
Molecular characterization of Mycobacterium tuberculosis (MTB) is important to understand the pathogenesis, diagnosis, treatment, and prevention of tuberculosis (TB). However, there is limited information on molecular characteristics and drug-resistant patterns of MTB in patients with extra-pulmonary tuberculosis (EPTB) in Ethiopia. Thus, this study aimed to determine the molecular characteristics and drug resistance patterns of MTB in patients with EPTB in Addis Ababa, Ethiopia. This study was conducted on frozen stored isolates of EPTB survey conducted in Addis Ababa, Ethiopia. A drug susceptibility test was performed using BACTEC-MGIT 960. Species and strain identification were performed using the Geno-Type MTBC and spoligotyping technique, respectively. Data were entered into the MIRU-VNTRplus database to assess the spoligotype patterns of MTB. Analysis was performed using SPSS version 23, and participants' characteristics were presented by numbers and proportions. Of 151 MTB isolates, 29 (19.2%) were resistant to at least one drug. The highest proportion of isolates was resistant to Isoniazid (14.6%) and Pyrazinamide (14.6%). Nine percent of isolates had multidrug-resistant TB (MDR-TB), and 21.4% of them had pre-extensively drug-resistant TB (pre-XDR-TB). Among the 151 MTB isolates characterized by spoligotyping, 142 (94.6%) had known patterns, while 9 (6.0%) isolates were not matched with the MIRU-VNTRplus spoligotype database. Of the isolates which had known patterns, 2% was M.bovis while 98% M. tuberculosis. Forty-one different spoligotype patterns were identified. The most frequently identified SpolDB4 (SIT) wereSIT149 (21.2%), SIT53 (14.6%) and SIT26 (9.6%). The predominant genotypes identified were T (53.6%), Central Asia Strain (19.2%) and Haarlem (9.9%). The present study showed a high proportion of MDR-TB and pre-XDR-TB among EPTB patients. The strains were mostly grouped into SIT149, SIT53, and SIT26. The T family lineage was the most prevalent genotype. MDR-TB and pre-XDR-TB prevention is required to combat these strains in EPTB. A large scale study is required to describe the molecular characteristics and drug resistance patterns of MTB isolates in EPTB patients.
Sections du résumé
BACKGROUND
Molecular characterization of Mycobacterium tuberculosis (MTB) is important to understand the pathogenesis, diagnosis, treatment, and prevention of tuberculosis (TB). However, there is limited information on molecular characteristics and drug-resistant patterns of MTB in patients with extra-pulmonary tuberculosis (EPTB) in Ethiopia. Thus, this study aimed to determine the molecular characteristics and drug resistance patterns of MTB in patients with EPTB in Addis Ababa, Ethiopia.
METHODS
This study was conducted on frozen stored isolates of EPTB survey conducted in Addis Ababa, Ethiopia. A drug susceptibility test was performed using BACTEC-MGIT 960. Species and strain identification were performed using the Geno-Type MTBC and spoligotyping technique, respectively. Data were entered into the MIRU-VNTRplus database to assess the spoligotype patterns of MTB. Analysis was performed using SPSS version 23, and participants' characteristics were presented by numbers and proportions.
RESULTS
Of 151 MTB isolates, 29 (19.2%) were resistant to at least one drug. The highest proportion of isolates was resistant to Isoniazid (14.6%) and Pyrazinamide (14.6%). Nine percent of isolates had multidrug-resistant TB (MDR-TB), and 21.4% of them had pre-extensively drug-resistant TB (pre-XDR-TB). Among the 151 MTB isolates characterized by spoligotyping, 142 (94.6%) had known patterns, while 9 (6.0%) isolates were not matched with the MIRU-VNTRplus spoligotype database. Of the isolates which had known patterns, 2% was M.bovis while 98% M. tuberculosis. Forty-one different spoligotype patterns were identified. The most frequently identified SpolDB4 (SIT) wereSIT149 (21.2%), SIT53 (14.6%) and SIT26 (9.6%). The predominant genotypes identified were T (53.6%), Central Asia Strain (19.2%) and Haarlem (9.9%).
CONCLUSION
The present study showed a high proportion of MDR-TB and pre-XDR-TB among EPTB patients. The strains were mostly grouped into SIT149, SIT53, and SIT26. The T family lineage was the most prevalent genotype. MDR-TB and pre-XDR-TB prevention is required to combat these strains in EPTB. A large scale study is required to describe the molecular characteristics and drug resistance patterns of MTB isolates in EPTB patients.
Identifiants
pubmed: 33284842
doi: 10.1371/journal.pone.0243493
pii: PONE-D-20-17590
pmc: PMC7721190
doi:
Substances chimiques
Antitubercular Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0243493Subventions
Organisme : FIC NIH HHS
ID : D43 TW009127
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Antimicrob Agents Chemother. 2017 Aug 24;61(9):
pubmed: 28630193
BMC Microbiol. 2015 Nov 21;15:268
pubmed: 26589993
Tuberculosis (Edinb). 2013 Jan;93(1):75-83
pubmed: 23140853
Int J Tuberc Lung Dis. 1999 Jul;3(7):632-4
pubmed: 10423227
Eur J Clin Microbiol Infect Dis. 2007 Feb;26(2):151-2
pubmed: 17256112
BMC Infect Dis. 2019 Feb 6;19(1):116
pubmed: 30728001
Indian J Med Res. 2014 Jul;140(1):116-22
pubmed: 25222786
Indian J Med Microbiol. 2015 Apr-Jun;33(2):267-70
pubmed: 25865980
Cold Spring Harb Perspect Med. 2015 Apr 27;5(9):a017863
pubmed: 25918181
J Med Microbiol. 2010 Mar;59(Pt 3):285-294
pubmed: 19959631
FEMS Immunol Med Microbiol. 2012 Oct;66(1):20-36
pubmed: 22574812
Ther Adv Infect Dis. 2014 Apr;2(2):61-70
pubmed: 25165556
Trop Med Int Health. 2017 Jun;22(6):703-707
pubmed: 28374900
Int J Tuberc Lung Dis. 2017 Oct 1;21(10):1112-1117
pubmed: 28911354
Lung India. 2019 Jan-Feb;36(1):3-7
pubmed: 30604698
Clin Respir J. 2018 Jun;12(6):2101-2109
pubmed: 29424965
PLoS One. 2014 Sep 23;9(9):e99659
pubmed: 25248118
Emerg Infect Dis. 2019 Mar;25(3):457-464
pubmed: 30789144
J Postgrad Med. 2012 Jul-Sep;58(3):185-9
pubmed: 23023350
Int J Tuberc Lung Dis. 2019 Aug 1;23(8):900-906
pubmed: 31533879
BMC Palliat Care. 2017 Nov 16;16(1):53
pubmed: 29145841
BMC Microbiol. 2006 Mar 06;6:23
pubmed: 16519816
J Clin Microbiol. 1997 Apr;35(4):907-14
pubmed: 9157152
Tuberc Respir Dis (Seoul). 2015 Apr;78(2):47-55
pubmed: 25861336
PLoS One. 2020 Feb 13;15(2):e0229040
pubmed: 32053661
Indian J Med Res. 2015 Nov;142(5):568-74
pubmed: 26658592
Scand J Infect Dis. 2013 Jul;45(7):512-8
pubmed: 23477546
Antimicrob Agents Chemother. 2018 Feb 23;62(3):
pubmed: 29263056
Korean J Intern Med. 2015 May;30(3):325-34
pubmed: 25995663
BMC Infect Dis. 2017 Dec 28;17(1):795
pubmed: 29282012
J Clin Diagn Res. 2015 Apr;9(4):EE01-6
pubmed: 26023563
PLoS One. 2019 Sep 16;14(9):e0222402
pubmed: 31525214
Clin Microbiol Infect. 2009 Jun;15(6):538-43
pubmed: 19302095
Med Sci (Basel). 2020 Jan 25;8(1):
pubmed: 31991795
Int J Tuberc Lung Dis. 2019 Feb 1;23(2):151-156
pubmed: 30621814
BMC Infect Dis. 2015 Oct 26;15:456
pubmed: 26503529
J Clin Microbiol. 2005 Sep;43(9):4357-62
pubmed: 16145077